Mice Model Market Size & Share, by Technology (CRISPR/Cas9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer, Other Technologies); Type; End user; Application; Disease Type; Service- Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

Mice Model Market - Regional Analysis

North America Market Insights

The North America mice model market is dominating and is expected to hold the revenue share of 41.8% by 2035. The market is leading the position via a powerful combination of substantial public funding and intense private sector research and development. The region’s preeminence is fundamentally driven by the scale of the U.S. National Institutes of Health budget, which exceed billion directly financing a vast portion of the academic and basic research that utilizes murine models. The dense concentration of global pharmaceutical and biotechnology companies on the continent channels annual private R&D expenditure, creating a sustained high-value demand for advanced genetically engineered and humanized models essential for drug discovery pipelines. This ecosystem is further reinforced by stringent regulatory frameworks from agencies like the FDA, which emphasize robust preclinical data, thereby elevating requirements for model quality, validation, and comprehensive phenotypic characterization.

The U.S. mice model market is strongly underpinned by the federally funded infrastructure, with the NIH supported Mutant Mouse Resource and Research Center serving as a central pillar of national supply and quality assurance. The NLM study in September 2024 depicts that the MMRRC maintains an archive covering nearly 65,000 alleles and has fulfilled over 20,000 orders for 13,651 scientists across 8,441 institutions worldwide demonstrating the scale and consistency of demand for disease relevant mouse models originating from the U.S. Its nationwide network of four regional centers and a centralized informatics coordination and service center illustrates how public investment has created an integrated ecosystem for model acquisition cryopreservation validation and global distribution. Beyond distributing the MMRRC’s service portfolio spanning genetic testing, microbiome analysis, phenotyping, breeding colony management, and infectious disease surveillance mirrors the commercial service stack of the broader mice model market, reinforcing the role of the public sector as both a demand anchor and a standards setter.

Mutant Mouse Strains Accepted into the MMRRC Program

Source: NLM September 2024

The Canada mice model market is defined by the strategic government investment in a specialized research cluster and a strong focus on translational science. Major funding is channeled via the Canadian Institutes of Health Research. The CIHR report in March 2025 depicts that they have invested over USD 1 billion annually in health research. A key trend is the leveraging of national infrastructure, such as the Centre for Phenogenomics in Toronto, which provides centralized state-of-the-art model generation and phenotyping services, maximizing resource efficiency for academia and industry. The government strategies, including the Pan-Canadian Artificial Intelligence Strategy, are driving the demand for advanced models that generate complex data sets for computational analysis in fields such as neurobiology. This focus on collaborative data-intensive research using standardized models positions Canada as an innovative niche market increasingly integrated with U.S. biopharma pipelines.

APAC Market Insights

The Asia Pacific mice model market is the fastest growing and is expected to grow at a CAGR of 9.2% during the forecast period 2026 to 2035. The market is driven by the government investment in biotechnology and a rapidly expanding domestic pharmaceutical R&D sector. China is the central engine of this growth, with the government initiatives such as the Made in China 2025 plan prioritizing biopharma innovation. This is evidenced by the National Natural Science Foundation of China awarding significant amount in research grants directly fueling the demand for the advanced models. Japan remains a mature, high-quality market with strength in advanced model generation, while India and South Korea are emerging as powerful hubs for cost-effective research and contract services. The key regional trend is the shift from the reliance on imported Western models to the development of local state-supported breeding and genetic engineering facilities aiming for self-sufficiency and catering to the region-specific disease research.

Large scale government investment in next-gen disease modeling led by initiatives such as the National Human Disease Animal Model Resource Center is driving the China mice model market. The NLM study in March 2023 depicts that the program responds directly to a structural gap identified in current research, that while 8,916 mutant mouse lines have been phenotyped globally under public programs such as the Knockout Mouse Project, many single-gene models show limited translational relevance for complex human diseases. As a result, China is repositioning its national infrastructure toward multi-gene comorbidity and genetically diverse mouse models for high burden conditions, including cancer, cardiovascular disease, and other neurodegenerative disorders. The NAMR’s mandate to create, preserve, and distribute advanced disease models, combined with its reported distribution of over 2,000 live engineered mice in 2022, signals the emergence of a state-backed supply ecosystem.

The Japan mice model market is closely tied to sustained government investment in medical research. The Science, Technology, and Innovation Japan in July 2023 depicts that JPY 17.5 billion is allocated for healthcare-related R&D under the Cabinet Office’s Science and Technology Innovation Creation and Promotion Funds. With 11.65 billion JPY earmarked as the President’s discretionary funding across 143 priority projects, this flexible financing structure is designed to surge the translational and clinical-oriented research areas where the murine models remain essential for disease mechanism studies, target validation, and early safety assessment. The emphasis on rapid needs-based funding decisions supports faster procurement cycles for genetically engineered mice breeding services, phenotyping, and colony management, mainly within national universities, public research institutes, and government hospitals.

Europe Market Insights

The Europe mice model market is defined by strong regulatory frameworks, significant public investment in biomedical research, and a collaborative academic industry ecosystem. The key growth is driven by the major EU funding programs such as Horizon Europe, which has a significant budget with substantial portions dedicated to health and biotechnology research that relies on animal models. The trends include a push towards the 3Rs principle, which is increasing the demand for the higher quality genetically defined models that provide more relevant data using fewer animals. This focus aligns with the EU directives and initiatives from the European Partnership for Alternative Approaches to Animal Testing. Further, the consolidation of research and drug development activity in key bioclusters such as the UK’s Golden Triangle, Germany's BioRegionen, and France's Genopole, creates concentrated, high-value demand for sophisticated models, particularly in oncology, neuroscience, and rare diseases.

The Germany mice model market is strongly supported by its leadership in rare disease and functional genomics research, exemplified by the work of the German Mouse Clinic within the International Mouse Phenotyping Consortium and INFRAFRONTIER. The NLM study in June 2023 shows that only a few hundred of nearly 7,000 rare diseases have approved therapies. Germany’s public research ecosystem is increasingly reliant on knockout mouse models to establish gene-disease causality and advance the translational pathways. The GMC’s systematic phenotyping of single gene KO mutants for monogenic rare diseases covering targets such as Nacc1, Bach2, Klotho, and newly characterized genes, including Kans111, Acsf3, and Rabgap1, illustrates how national and pan-European infrastructure is driving the sustained demand for genetically engineered mice deep phenotyping services and cross-border model distribution.

The UK mice model market is driven by the combination of a strong regulatory oversight and demand from the publicly funded biomedical and safety research. The Government of the UK in November 2025 reported that the UK recorded 2.64 million regulated scientific procedures involving animals under the Animals Act, with 95% using rodents, fish, and birds, underscoring the central role of mice in national research infrastructure. Nearly 46% of all procedures were dedicated to the creation and breeding of genetically altered animals, of which 99% were mice, which first reflects the growing dependence on engineered mouse models for understanding gene function and developing disease-relevant systems for oncology, neurology, and immunology. The core research fields driving this demand include the nervous system (170,880 procedures), immune system (137,113), and cancer research (101,418), while the regulatory toxicity testing accounted for over 156,900 procedures, anchoring the steady procurement from pharmaceutical and safety assessment pipelines.